Rezivertinib hydrochloride

(Synonyms: BPI-7711 hydrochloride)
1 Cited Publications
Avis client

Based on 1 publication(s) in Google Scholar

Rezivertinib (BPI-7711) hydrochloride is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib hydrochloride exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib hydrochloride has excellent central nervous system (CNS) penetration and has antitumor activity, such as non-small cell lung cancer (NSCLC).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • CAS No.: 2170255-78-2
  • Formule: C27H31ClN6O3
  • Masse moléculaire:523.03
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Rezivertinib hydrochloride

More

Voir tous les produits spécifiques à Isoform EGFR

More
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00